JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

• Market Cap: ₹1.09B
• Dividend Yield: N/A
• Average Volume (3M): 16.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 14.60%
• EPS Growth: -701.16%
• Country: IN
• Employees: 250
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Household & Personal Products
• EPS (TTM): 0.12
• Shares Outstanding: 85,603,966
• 10 Day Avg. Volume: 16,348
• 30 Day Avg. Volume: 16,781
• PEG Ratio: -0.01
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 1.06
• P/FCF Ratio: -6.22
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ₹11.50 ▼(-13.60% Downside)

The overall stock score of 47 reflects significant financial challenges and valuation concerns. The company's consistent losses and negative cash flows are major risks, while technical indicators suggest a bearish trend. The absence of a dividend yield and negative P/E ratio further impact the stock's attractiveness.

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description

JHS Svendgaard Laboratories Limited (JHS) is a leading player in the oral care and personal care industry, primarily based in India. The company specializes in the manufacturing and marketing of a diverse range of oral hygiene products, including toothpaste, mouthwash, and toothbrushes. Additionally, JHS engages in contract manufacturing for various brands, expanding its footprint in both domestic and international markets. With a focus on innovation and quality, JHS caters to a growing demand for effective and affordable personal care solutions.

How the Company Makes Money

JHS generates revenue through multiple streams, primarily by selling its own branded products as well as providing contract manufacturing services for other companies in the oral care sector. The company benefits from economies of scale due to its manufacturing capabilities, which allow it to produce goods at a lower cost. Key revenue streams include sales from proprietary brands, such as various toothpaste and oral hygiene products, and income from contracts with third-party brands looking to leverage JHS's manufacturing expertise. Strategic partnerships with distributors and retail chains also contribute significantly to its earnings, enabling the company to reach a broader customer base and enhance its market presence.

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary

JHS Svendgaard Laboratories Limited faces significant financial challenges. The income statement indicates declining revenue and consistent unprofitability since 2021. Despite a strong equity position and low financial leverage, negative cash flows and poor operating performance highlight operational inefficiencies and profitability issues.

Income Statement

The income statement shows a declining trajectory in revenue, with a significant drop from 2020 to 2025. Gross profit margin improved to 33.66% in 2025, indicating better cost management. However, the company has been unprofitable since 2021, with a negative net profit margin of -21.47% in 2025. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows a strong equity position with an equity ratio of 85.83% in 2025, suggesting financial stability. The debt-to-equity ratio remains low at 0.037, which indicates low financial leverage. However, the return on equity is negative due to consistent losses, highlighting profitability issues.

Cash Flow

Cash flow analysis reveals a negative free cash flow in recent years, with a significant deterioration in 2025. The operating cash flow to net income ratio indicates challenges in converting revenue into cash, with a negative ratio in 2025. Despite positive financing cash flow, the company struggles with liquidity due to poor operating performance.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	909.67M	919.97M	698.06M	840.82M	854.91M	1.00B
Gross Profit	303.64M	309.55M	203.55M	165.45M	201.68M	264.03M
EBITDA	-36.20M	-39.92M	33.78M	-163.82M	85.45M	94.57M
Net Income	-180.60M	-197.44M	-40.58M	-175.17M	-40.52M	11.98M
Balance Sheet
Total Assets	0.00	2.01B	1.97B	2.28B	2.22B	2.28B
Cash, Cash Equivalents and Short-Term Investments	195.43M	200.16M	94.56M	386.51M	80.19M	230.38M
Total Debt	0.00	64.58M	51.29M	155.09M	61.82M	70.11M
Total Liabilities	-1.73B	284.41M	271.70M	543.87M	269.46M	299.97M
Stockholders Equity	1.73B	1.73B	1.70B	1.74B	1.86B	1.89B
Cash Flow
Free Cash Flow	0.00	-157.11M	-401.17M	89.43M	-158.75M	36.96M
Operating Cash Flow	0.00	-51.78M	-85.84M	232.86M	-91.36M	120.29M
Investing Cash Flow	0.00	-220.18M	-217.34M	96.77M	-46.97M	-22.25M
Financing Cash Flow	0.00	232.97M	21.74M	-9.00M	-16.72M	103.09M

JHS Svendgaard Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.31
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Positive. The current price of 13.31 is above the 20-day moving average (MA) of 11.98, above the 50-day MA of 11.52, and below the 200-day MA of 13.72, indicating a neutral trend. The MACD of 0.57 indicates Negative momentum. The RSI at 68.18 is Neutral, neither overbought nor oversold. The STOCH value of 87.99 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GROBTEA	―	₹1.17B	18.79	―	0.29%	9.17%	124.99%
Sector *	―	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
NAGREEKEXP	―	₹892.17M	32.96	―	―	-25.40%	-69.05%
JHS	―	₹1.09B	―	―	―	14.60%	-701.16%

JHS Svendgaard Laboratories Limited Corporate Events

JHS Svendgaard Laboratories Holds 21st AGM Virtually

JHS Svendgaard Laboratories Limited conducted its 21st Annual General Meeting (AGM) on September 20, 2025, via video conferencing, adhering to regulatory guidelines. The meeting was chaired by Mr. R.C. Venkateish, with key directors and officers in attendance, and was held with a quorum of 89 members. The AGM proceedings, including the notice and related documents, were made available electronically to shareholders and on the company’s website.

JHS Svendgaard Laboratories Prepares for Virtual AGM with Shareholder Engagement

JHS Svendgaard Laboratories Limited announced the dispatch of its Annual Report and Notice for the 21st Annual General Meeting (AGM) to its shareholders. The AGM is scheduled for September 20, 2025, and will be conducted via video conferencing. This announcement is part of the company’s compliance with regulatory requirements, ensuring transparency and engagement with its stakeholders.